Literature DB >> 36266269

S100A7 attenuates immunotherapy by enhancing immunosuppressive tumor microenvironment in lung squamous cell carcinoma.

Chengming Liu1, Sufei Zheng1, Zhiliang Lu1, Zhanyu Wang1, Sihui Wang1, Xiaoli Feng2, Yan Wang3, Nan Sun4, Jie He5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 36266269      PMCID： PMC9584899          DOI： 10.1038/s41392-022-01196-4

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN： 2059-3635


× No keyword cloud information.
  5 in total

Review 1.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.

Authors:  Ryuma Tokunaga; Wu Zhang; Madiha Naseem; Alberto Puccini; Martin D Berger; Shivani Soni; Michelle McSkane; Hideo Baba; Heinz-Josef Lenz
Journal:  Cancer Treat Rev       Date:  2017-11-26       Impact factor: 12.111

2.  Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.

Authors:  Imran G House; Peter Savas; Phillip K Darcy; Paul A Beavis; Junyun Lai; Amanda X Y Chen; Amanda J Oliver; Zhi L Teo; Kirsten L Todd; Melissa A Henderson; Lauren Giuffrida; Emma V Petley; Kevin Sek; Sherly Mardiana; Tuba N Gide; Camelia Quek; Richard A Scolyer; Georgina V Long; James S Wilmott; Sherene Loi
Journal:  Clin Cancer Res       Date:  2019-10-21       Impact factor: 12.531

3.  The TGFβ-induced lncRNA TBILA promotes non-small cell lung cancer progression in vitro and in vivo via cis-regulating HGAL and activating S100A7/JAB1 signaling.

Authors:  Zhiliang Lu; Yuan Li; Yun Che; Jianbing Huang; Shouguo Sun; Shuangshuang Mao; Yuanyuan Lei; Ning Li; Nan Sun; Jie He
Journal:  Cancer Lett       Date:  2018-06-15       Impact factor: 8.679

4.  S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis.

Authors:  Zhiliang Lu; Sufei Zheng; Chengming Liu; Xinfeng Wang; Guochao Zhang; Feng Wang; Sihui Wang; Jianbing Huang; Shuangshuang Mao; Yuanyuan Lei; ZhanYu Wang; Nan Sun; Jie He
Journal:  Clin Transl Med       Date:  2021-07

5.  Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.

Authors:  Matthew A Coelho; Sophie de Carné Trécesson; Sareena Rana; Davide Zecchin; Christopher Moore; Miriam Molina-Arcas; Philip East; Bradley Spencer-Dene; Emma Nye; Karin Barnouin; Ambrosius P Snijders; Wi S Lai; Perry J Blackshear; Julian Downward
Journal:  Immunity       Date:  2017-12-12       Impact factor: 31.745
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.